Baijin Life Science Holdings Limited
MNNGF
$0.08
$0.000.00%
OTC PK
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 153.54% | 103.91% | 60.82% | 3.10% | -38.09% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 153.54% | 103.91% | 60.82% | 3.10% | -38.09% |
| Cost of Revenue | 164.00% | 75.30% | 21.95% | -21.97% | -54.92% |
| Gross Profit | 132.97% | 234.45% | 922.45% | 334.36% | 132.29% |
| SG&A Expenses | 27.44% | 41.55% | 58.58% | 85.91% | 140.12% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -632.03% | -666.39% | 82.73% | 130.93% | 287.32% |
| Total Operating Expenses | 77.79% | 56.32% | 38.19% | 3.95% | -26.11% |
| Operating Income | 250.49% | 133.63% | 46.30% | -10.45% | -359.48% |
| Income Before Tax | 83.88% | 44.62% | -41.39% | -395.49% | -198.66% |
| Income Tax Expenses | -8,390.00% | 8,390.00% | -- | -- | -- |
| Earnings from Continuing Operations | 99.07% | 33.99% | -108.88% | -451.07% | -198.84% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -119.39% | -413.96% | -- | -- | -- |
| Net Income | 96.07% | -2.79% | -191.99% | -496.02% | -186.16% |
| EBIT | 250.49% | 133.63% | 46.30% | -10.45% | -359.48% |
| EBITDA | 290.48% | 155.91% | 59.71% | 3.05% | -367.61% |
| EPS Basic | 85.71% | -9.09% | -175.00% | -400.00% | -170.00% |
| Normalized Basic EPS | 300.00% | 128.57% | -300.00% | -425.00% | -183.33% |
| EPS Diluted | 85.71% | -9.09% | -175.00% | -400.00% | -170.00% |
| Normalized Diluted EPS | 300.00% | 128.57% | -300.00% | -425.00% | -183.33% |
| Average Basic Shares Outstanding | 7.58% | 5.74% | 3.89% | 5.35% | 6.89% |
| Average Diluted Shares Outstanding | 7.58% | 5.74% | 3.89% | 5.35% | 6.89% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |